[关键词]
[摘要]
目的 探讨脾氨肽口服冻干粉联合布地奈德治疗小儿支气管肺炎的临床疗效与安全性。方法 选取2016年5月-2017年5月在武汉大学人民医院诊治的小儿支气管肺炎患儿154例,根据治疗方案不同分成对照组和治疗组,每组各77例。对照组患儿雾化吸入吸入用布地奈德混悬液,1 mg/次,2次/d;治疗组患儿在对照组的基础上口服脾氨肽口服冻干粉,2 mg/次。两组患儿均连续治疗7 d。观察两组患儿临床疗效,同时比较治疗前后两组患儿临床症状消退时间、肺功能、血气分析指标和不良反应情况。结果 治疗后,对照组临床总有效率为85.71%,显著低于治疗组的96.10%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患儿肺部啰音消失时间、咳嗽消失时间及退热时间等均显著短于对照组患儿(P<0.05)。治疗后,两组患儿静息通气量(MV)、潮气量(VT)和动脉血氧分压(pO2)显著升高(P<0.05),动脉二氧化碳分压(pCO2)显著降低(P<0.05),且治疗组肺功能和血气分析指标明显优于对照组(P<0.05)。治疗期间,治疗组不良反应发生率为2.60%,明显低于对照组的12.99%,两组比较差异具有统计学意义(P<0.05)。结论 脾氨肽口服冻干粉联合布地奈德治疗小儿支气管肺炎疗效明显,能够显著改善患儿的肺功能及缺氧状态,安全性好,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy and safety of Spleen Aminopeptide Oral Lyophilized Powder combined with budesonide in treatment of children with Bronchopneumonia. Methods Children (154 cases) with bronchopneumonia in Renmin Hospital of Wuhan University from May 2016 to May 2017 were divided into control and treatment groups based on different treatment, and each group had 77 cases. Children in the control group were atomization inhalation administered with Budesonide Suspension for inhalation, 1 mg/time, twice daily. Children in the treatment group were po administered with Spleen Aminopeptide Oral Lyophilized Powder on the basis of the control group, 2 mg/time. Children in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the lung function and blood gas analysis, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.71%, which was significantly lower than 96.10% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of pulmonary rales and cough, and fever reducing time in the treatment group after treatment was significantly shorter than that in the control group (P < 0.05). After treatment, the MV, VT and PaO2 levels in two groups were significantly increased (P < 0.05), PaCO2 levels were significantly decreased (P < 0.05), and the lung function and blood gas analysis in the treatment group after treatment were significantly better than that in the control group (P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 2.60%, which was significantly lower than 12.99% in the control group, with significant difference between two groups (P < 0.05).. Conclusion Spleen Aminopeptide Oral Lyophilized Powder combined with budesonide has obvious curative effect on bronchopneumonia, can significantly improve the lung function and hypoxia status with high safety, which has a certain clinical application value.
[中图分类号]
[基金项目]